These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7601186)

  • 1. Tumour-associated trypsin inhibitor and renal cell carcinoma.
    Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
    Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients.
    Lukkonen A; Lintula S; von Boguslawski K; Carpén O; Ljungberg B; Landberg G; Stenman UH
    Int J Cancer; 1999 Nov; 83(4):486-90. PubMed ID: 10508484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer.
    Pecchio F; Rapellino M; Baldi S; Casali V; Libertucci D; Coni F
    Scand J Clin Lab Invest Suppl; 1991; 207():63-4. PubMed ID: 1780695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma.
    Tornberg SV; Nisen H; Järvinen P; Järvinen R; Kilpeläinen TP; Taari K; Stenman UH; Visapää H
    Scand J Urol; 2020 Oct; 54(5):413-419. PubMed ID: 32748674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
    Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
    Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
    Medl M; Ogris E; Peters-Engl C; Leodolter S
    Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
    Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
    Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
    Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
    Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tumour-associated trypsin inhibitor (TATI) and renal function.
    Tramonti G; Donadio C; Ferdeghini M; Annichiarico C; Norpoth M; Bianchi R; Bianchi C
    Scand J Clin Lab Invest; 1996 Nov; 56(7):653-6. PubMed ID: 8981662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
    Catarino M; Conde R
    Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
    Halila H; Lehtovirta P; Stenman UH
    Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.
    Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K
    BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
    Peters-Engl C; Medl M; Ogris E; Leodolter S
    Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis.
    Medl M; Ogris E; Peters-Engl C; Mierau M; Buxbaum P; Leodolter S
    Br J Obstet Gynaecol; 1997 Jan; 104(1):78-81. PubMed ID: 8988701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.
    Järvisalo J; Hakama M; Knekt P; Stenman UH; Leino A; Teppo L; Maatela J; Aromaa A
    Cancer; 1993 Mar; 71(6):1982-8. PubMed ID: 8443749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.
    Venesmaa P; Lehtovirta P; Stenman UH; Leminen A; Forss M; Ylikorkala O
    Br J Cancer; 1994 Dec; 70(6):1188-90. PubMed ID: 7981075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
    Piantino P; Arosaio E
    Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-associated trypsin inhibitor (TATI) in bone diseases.
    Rapellino M; Pecchio F; Broggi S; Baldi C; Ricardi G; Libertucci D
    Scand J Clin Lab Invest Suppl; 1991; 207():65-6. PubMed ID: 1780696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma.
    Gion M; Mione R; Tremolada C; Dalla Palma P; Ruol A; Dittadi R; Leon A; Nosadini A; Castoro C; Bruscagnin G
    Scand J Clin Lab Invest Suppl; 1991; 207():37-41. PubMed ID: 1780688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Rispoli G; Prontera C; Bianchi R; Fioretti P
    Scand J Clin Lab Invest Suppl; 1991; 207():19-24. PubMed ID: 1780685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.